Works by Shi, Yuankai

Results: 173
    1
    2

    Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

    Published in:
    EJHaem, 2022, v. 3, n. 4, p. 1154, doi. 10.1002/jha2.517
    By:
    • Zhu, Jun;
    • Hong, Xiaonan;
    • Song, Yu Qin;
    • Hodkinson, Brendan;
    • Balasubramanian, Sriram;
    • Wang, Songbai;
    • Zhang, Qingyuan;
    • Shi, Yuankai;
    • Huang, Huiqiang;
    • Zhang, Huilai;
    • Zhu, Yan;
    • Shreeve, Stephen Martin;
    • Sun, Steven;
    • Wang, Ze;
    • Wang, Xiaocan;
    • Fan, Yue;
    • Wilson, Wyndham;
    • Vermeulen, Jessica
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

    Published in:
    BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02738-5
    By:
    • Shi, Yuankai;
    • Chen, Jianhua;
    • Zhang, Helong;
    • Zhang, Zhihong;
    • Zhang, Yiping;
    • Wang, Zhehai;
    • Zhang, Shucai;
    • Zhao, Jian;
    • Liu, Chunling;
    • Wang, Xiuwen;
    • Zhao, Yanqiu;
    • Hu, Changlu;
    • Yang, Lei;
    • Hao, Xuezhi;
    • Wang, Lin;
    • Liu, Yunpeng;
    • Yu, Yan;
    • Zhao, Jun;
    • Wang, Mengzhao;
    • Zhang, Liangming
    Publication type:
    Article
    15

    Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.

    Published in:
    BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-022-02692-8
    By:
    • Shi, Yuankai;
    • Zhou, Jianying;
    • Zhao, Yanqiu;
    • Zhu, Bo;
    • Zhang, Liangming;
    • Li, Xingya;
    • Fang, Jian;
    • Shi, Jianhua;
    • Zhuang, Zhixiang;
    • Yang, Sheng;
    • Wang, Donglin;
    • Yu, Huiqing;
    • Zhang, Longzhen;
    • Zheng, Rongsheng;
    • Greco, Michael;
    • Wang, Tingting
    Publication type:
    Article
    16
    17
    18

    Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.

    Published in:
    BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13736-6
    By:
    • Shi, Yuankai;
    • Wang, Xinshuai;
    • Pei, Zhidong;
    • Shi, Huaqiu;
    • Zhang, Yanjun;
    • Yi, Tienan;
    • Mei, Jiazhuan;
    • Guo, Yanzhen;
    • Dong, Youhong;
    • Ma, Tianjiang;
    • Zhang, Qingyuan;
    • Jia, Xiaojing;
    • Zhu, Zhengqiu;
    • Xu, Shen;
    • Liu, Yanyan;
    • Niu, Hongrui;
    • Jiang, Weimei;
    • Jiang, Xiaodong;
    • Zhou, Shengyu;
    • Sun, Li
    Publication type:
    Article
    19
    20

    Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 5, p. 607, doi. 10.1002/ajh.25043
    By:
    • Gambacorti‐Passerini, Carlo;
    • Orlov, Sergey;
    • Zhang, Li;
    • Braiteh, Fadi;
    • Huang, Huiqiang;
    • Esaki, Taito;
    • Horibe, Keizo;
    • Ahn, Jin‐Seok;
    • Beck, Joseph T.;
    • Edenfield, William Jeffrey;
    • Shi, Yuankai;
    • Taylor, Matthew;
    • Tamura, Kenji;
    • Van Tine, Brian A.;
    • Wu, Shang‐Ju;
    • Paolini, Jolanda;
    • Selaru, Paulina;
    • Kim, Tae Min
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-022-10500-y
    By:
    • Hu, Xingsheng;
    • Cui, Xinge;
    • Wang, Ziping;
    • Liu, Yunpeng;
    • Luo, Ying;
    • Zhong, Wei;
    • Zhao, Hui;
    • Yao, Mengxing;
    • Jiang, Da;
    • Wang, Mingxia;
    • Chen, Minjiang;
    • Zheng, Xin;
    • Ding, Lieming;
    • Wang, Yang;
    • Yuan, Xiaobin;
    • Wu, Pengxiang;
    • Hu, Bei;
    • Han, Xiaohong;
    • Shi, Yuankai
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    Identification of novel prognostic autoantibodies in diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high‐throughput antigen microarray.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 8, p. 1257, doi. 10.1002/cncr.35158
    By:
    • Dai, Liyuan;
    • Chen, Haizhu;
    • Tan, Qiaoyun;
    • Wang, Yanrong;
    • Li, Lin;
    • Lou, Ning;
    • Fan, Guangyu;
    • Xie, Tongji;
    • Luo, Rongrong;
    • Wang, Shasha;
    • Zhou, Yu;
    • Zhong, Qiaofeng;
    • Yao, Jiarui;
    • Zhang, Zhishang;
    • Tang, Le;
    • Shi, Yuankai;
    • Han, Xiaohong
    Publication type:
    Article
    43
    44
    45
    46

    First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-025-02229-4
    By:
    • Shi, Yuankai;
    • Ba, Yi;
    • Wang, Junye;
    • Xiong, Jianping;
    • Gu, Kangsheng;
    • Chen, Yigui;
    • Zheng, Zhendong;
    • Wang, Zishu;
    • Guo, Weijian;
    • Cheng, Ying;
    • Yin, Xianli;
    • Liu, Yunpeng;
    • Bai, Yuxian;
    • Li, Enxiao;
    • Li, Qi;
    • Zhu, Liangjun;
    • Li, Wei;
    • Jiang, Da;
    • He, Jingdong;
    • Chen, Jiansi
    Publication type:
    Article
    47

    Medication therapy of high‐dose methotrexate: An evidence‐based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society.

    Published in:
    British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2456, doi. 10.1111/bcp.15134
    By:
    • Song, Zaiwei;
    • Hu, Yang;
    • Liu, Shuang;
    • Wang, Guanru;
    • Zhai, Suodi;
    • Zhang, Xianglin;
    • Li, Youping;
    • Du, Guanhua;
    • Shi, Yuankai;
    • Chen, Yaolong;
    • Dong, Mei;
    • Guo, Ruichen;
    • Guo, Wei;
    • Huang, Hongbing;
    • Huang, Xiaojun;
    • Jing, Hongmei;
    • Ke, Xiaoyan;
    • Li, Guohui;
    • Miao, Liyan;
    • Niu, Xiaohui
    Publication type:
    Article
    48
    49

    Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.

    Published in:
    Head & Neck, 2015, v. 37, n. 8, p. 1081, doi. 10.1002/hed.23707
    By:
    • Guo, Ye;
    • Shi, Mei;
    • Yang, Ankui;
    • Feng, Jifeng;
    • Zhu, Xiaodong;
    • Choi, Young‐Jin;
    • Hu, Guoqin;
    • Pan, Jianji;
    • Hu, Chunhong;
    • Luo, Rongcheng;
    • Zhang, Yiping;
    • Zhou, Liang;
    • Cheng, Ying;
    • Lüpfert, Christian;
    • Cai, Junliang;
    • Shi, yuankai
    Publication type:
    Article
    50